Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).

@article{Chaudhuri2016PretreatmentNL,
  title={Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).},
  author={Aadel A. Chaudhuri and Michael S Binkley and J. Brian Rigdon and Justin Nathaniel Carter and Sonya Aggarwal and Sara A Dudley and Yushen Qian and Kiran A. Kumar and Wendy Y Hara and Michael Francis Gensheimer and Viswam S. Nair and Peter G. Maxim and David Benjamin Shultz and Karl Kenneth Bush and Nicholas Trakul and Quynh L{\^e} and Maximilian Diehn and Billy W. Loo and Haiwei Henry Guo},
  journal={Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology},
  year={2016},
  volume={119 3},
  pages={454-60}
}
PURPOSE To determine if pre-treatment non-target lung FDG-PET uptake predicts for symptomatic radiation pneumonitis (RP) following lung stereotactic ablative radiotherapy (SABR). METHODS We reviewed a 258 patient database from our institution to identify 28 patients who experienced symptomatic (grade ⩾ 2) RP after SABR, and compared them to 57 controls… CONTINUE READING